Core Insights - Roche announced new data on Lunsumio® (mosunetuzumab) showcasing its potential in earlier treatment lines for lymphoma patients, presented at the 67th American Society of Hematology Annual Meeting [1] Group 1: Efficacy and Clinical Data - Lunsumio shows promise in combination with lenalidomide for relapsed or refractory follicular lymphoma (FL), with a complete response (CR) rate of 87.0% in a study of 54 patients [2] - In the phase Ib/II GO40516 study, Lunsumio combined with Polivy® demonstrated an overall response rate (ORR) of 77.5% for relapsed or refractory large B-cell lymphoma (LBCL), compared to 50.0% for the control group [3] - Five-year follow-up data from the phase II GO29781 study indicated a 5-year overall survival rate of 78.5% for Lunsumio IV in third-line or later FL [5] Group 2: Safety and Tolerability - Cytokine release syndrome (CRS) events were reported in 27.8% of patients receiving Lunsumio plus lenalidomide, with most being low grade [2] - Adverse events (AEs) in the GO40516 study included neutropenia (40%), infections (45%), and peripheral neuropathy (10%), with no new safety signals identified [3] Group 3: Regulatory and Market Position - Lunsumio is approved in over 60 countries for FL patients who have undergone at least two prior systemic therapies, with ongoing discussions for further approvals [6] - The European Commission recently approved Lunsumio for FL after two or more lines of systemic therapy, with a decision from the US FDA expected soon [7] Group 4: Strategic Development - Roche is committed to exploring new formulations and combinations of Lunsumio and other medicines to enhance patient outcomes and provide diverse treatment options [8] - The company has a robust clinical development program for Lunsumio, targeting various B-cell non-Hodgkin lymphomas and other blood cancers [9]

Core Insights - Roche will present 46 abstracts, including 12 oral presentations, at the 67th American Society of Hematology (ASH) Annual Meeting from December 6-9, 2025, showcasing advancements in its hematology portfolio [1][2] Group 1: Key Presentations and Findings - The data presented at ASH highlight Roche's commitment to innovation in hematology and progress in treating blood disorders, particularly in hemophilia A, lymphoma, and multiple myeloma [2][5] - Key presentations include findings on cevostamab for relapsed/refractory multiple myeloma, demonstrating high overall response rates (ORR) and durable remissions [4][9] - New data from the Beyond ABR study on Hemlibra® (emicizumab) show low bleeding rates and improved joint health in patients switching from factor VIII prophylaxis [6][11] Group 2: Pipeline Developments - NXT007, a next-generation bispecific antibody, shows promise in normalizing hemostasis in hemophilia A and is set to enter phase III clinical development in 2026 [6][14] - SPK-8011QQ, an investigational AAV gene therapy, demonstrates enhanced hemostatic potency compared to its predecessor, with a phase IIb study planned for 2026 [6][15] - Lunsumio® (mosunetuzumab) shows potential as an effective outpatient treatment for relapsed/refractory follicular lymphoma, with positive preliminary data from ongoing studies [6][12] Group 3: Clinical Outcomes and Patient Benefits - Long-term follow-up data indicate sustained clinical benefits and improved quality of life for patients treated with Lunsumio plus Polivy® (polatuzumab vedotin) [6][13] - Columvi® (glofitamab) continues to show superior survival outcomes in combination with gemcitabine and oxaliplatin for patients with relapsed/refractory diffuse large B-cell lymphoma [6][34] - The findings from various studies underscore Roche's ongoing efforts to redefine treatment standards and improve patient outcomes in hematology [5][18]